Shenzhen Lifotronic Technology Co (688389) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) has a cash flow conversion efficiency ratio of 0.025x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥53.10 Million ≈ $7.77 Million USD) by net assets (CN¥2.10 Billion ≈ $306.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Shenzhen Lifotronic Technology Co market cap and net worth for the company's overall valuation and market capitalisation.
Shenzhen Lifotronic Technology Co - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Shenzhen Lifotronic Technology Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shenzhen Lifotronic Technology Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Lifotronic Technology Co ranked by their cash flow conversion efficiency. Explore how high is Shenzhen Lifotronic Technology Co's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing WKW Automotive Parts Co Ltd
SHE:002662
|
0.036x |
|
Peoples Fin
NASDAQ:PFIS
|
0.026x |
|
Argus Shanghai Textile Chemicals Co Ltd
SHG:603790
|
0.021x |
|
Dakota Gold Corp.
NYSE MKT:DC
|
-0.063x |
|
Ruitai Materials Technology Co Ltd
SHE:002066
|
-0.153x |
|
Tronox Holdings PLC
NYSE:TROX
|
0.084x |
|
Jaya Sukses Makmur Sentosa Tbk PT
JK:RISE
|
-0.018x |
|
Shenzhen Sunwin Intelligent
SHE:300044
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Shenzhen Lifotronic Technology Co (2016–2025)
The table below shows the annual cash flow conversion efficiency of Shenzhen Lifotronic Technology Co from 2016 to 2025. View Shenzhen Lifotronic Technology Co stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.11 Billion ≈ $308.57 Million |
CN¥280.97 Million ≈ $41.11 Million |
0.133x | -7.90% |
| 2024-12-31 | CN¥2.05 Billion ≈ $299.89 Million |
CN¥296.47 Million ≈ $43.38 Million |
0.145x | -14.41% |
| 2023-12-31 | CN¥1.80 Billion ≈ $263.05 Million |
CN¥303.82 Million ≈ $44.46 Million |
0.169x | -10.21% |
| 2022-12-31 | CN¥1.44 Billion ≈ $211.23 Million |
CN¥271.71 Million ≈ $39.76 Million |
0.188x | +30.06% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.08 Million |
CN¥182.07 Million ≈ $26.64 Million |
0.145x | +21.33% |
| 2020-12-31 | CN¥1.14 Billion ≈ $167.34 Million |
CN¥136.42 Million ≈ $19.96 Million |
0.119x | +36.36% |
| 2019-12-31 | CN¥1.05 Billion ≈ $153.60 Million |
CN¥91.82 Million ≈ $13.44 Million |
0.087x | -27.94% |
| 2018-12-31 | CN¥668.39 Million ≈ $97.81 Million |
CN¥81.14 Million ≈ $11.87 Million |
0.121x | +102.24% |
| 2017-12-31 | CN¥587.25 Million ≈ $85.93 Million |
CN¥35.25 Million ≈ $5.16 Million |
0.060x | -20.50% |
| 2016-12-31 | CN¥370.82 Million ≈ $54.26 Million |
CN¥28.00 Million ≈ $4.10 Million |
0.076x | -- |
About Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. researches, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. It offers a comprehensive range of in vitro diagnostic equipment and reagents, including electrochemiluminescence immunoassay analyzers, glycated hemoglobin analyzers, specific protein analyzers, blo… Read more